Evidence-backed European AI register
Isomorphic Labs
Reviewed identity, roles, model listings, pricing and evidence for Isomorphic Labs.
Dataset compiled 2026-08-28 · evidence over inference
Reviewed identity
- Headquarters scope
- headquarters unknown
- Headquarters country
- unknown
- Headquarters city
- unknown
- Legal entity
- Ltd (UK private limited company)
- Ownership
- subsidiary of Alphabet Inc. (US) — Alphabet remains the majority/controlling shareholder alongside external investors
- Founded
- 2021
- Confidence
- high
- Last verified
- 2026-08-22
Headquarters evidence
No qualifying headquarters passage was promoted.
Reviewed sources show London presence and corporate control, but not explicit headquarters wording.
Evidence boundaries
Organisation listings identify a reviewed canonical record. Headquarters is independent of incorporation, registered offices, ownership, hosting and runtime. Model listings show an association in the source register; they do not by themselves establish model creation, current API availability, hosting location or infrastructure ownership.
Model listings
- AlphaFold 3
- Type
- multimodal
- Parameters
- unknown
- Context
- unknown
- Languages
- unknown
- Licence
- research/non-commercial for the public offering; commercial use retained by Isomorphic
- Release
- 2024-05
- Isomorphic Labs Drug Design Engine (IsoDDE)
- Type
- multimodal
- Parameters
- unknown
- Context
- unknown
- Languages
- unknown
- Licence
- proprietary
- Release
- unknown
Profile note
OWNERSHIP CAVEAT: London-headquartered and London-staffed, but an Alphabet subsidiary — CEO Demis Hassabis is simultaneously CEO of Google DeepMind. Recorded here (unlike Google DeepMind itself) because it is a separately capitalised company with its own external investors, its own $2.1B Series B in May 2026 — the largest AI-drug-discovery raise ever — and its own commercial deals with Eli Lilly and Novartis. Readers should still understand it as Alphabet-controlled, not independently European. Hassabis gave an end-of-2026 timeline for a first clinical entry at Davos in Jan 2026, a year later…
Record sources
- https://www.isomorphiclabs.com/our-tech
- https://www.isomorphiclabs.com/articles/the-isomorphic-labs-drug-design-engine-unlocks-a-new-frontier
- https://www.forbes.com/sites/amyfeldman/2026/05/13/isomorphic-labs-21-billion-fundraise-is-the-biggest-bet-ye…
- https://www.fiercebiotech.com/biotech/alphabets-ai-biotech-isomorphic-labs-bags-21b-series-b-fuel-next-gen-dr…
- https://www.isomorphiclabs.com/